Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
Purpose: Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were exclude...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 11, 2015
|
| In: |
PLOS ONE
Year: 2015, Volume: 10, Issue: 3 |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0118564 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1371/journal.pone.0118564 Verlag, kostenfrei, Volltext: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356548/ 
|
| Author Notes: | Lisa Zimmer, Julia Vaubel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus G. Griewank, Michael Fluck, Bastian Schilling, Dirk Schadendorf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1562886649 | ||
| 003 | DE-627 | ||
| 005 | 20230427122043.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170830s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0118564 |2 doi | |
| 035 | |a (DE-627)1562886649 | ||
| 035 | |a (DE-576)492886644 | ||
| 035 | |a (DE-599)BSZ492886644 | ||
| 035 | |a (OCoLC)1340978923 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zimmer, Lisa |d 1977- |e VerfasserIn |0 (DE-588)131597914 |0 (DE-627)511279620 |0 (DE-576)298613875 |4 aut | |
| 245 | 1 | 0 | |a Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma |c Lisa Zimmer, Julia Vaubel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus G. Griewank, Michael Fluck, Bastian Schilling, Dirk Schadendorf |
| 264 | 1 | |c March 11, 2015 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.08.2017 | ||
| 520 | |a Purpose: Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were excluded in these studies, the Dermatologic Cooperative Oncology Group (DeCOG) conducted a phase II to assess the efficacy and safety of ipilimumab in patients with metastatic UM. Patients and Methods: We undertook a multicenter phase II study in patients with different subtypes of metastatic melanoma. Here we present data on patients with metastatic UM (pretreated and treatment-naïve) who received up to four cycles of ipilimumab administered at a dose of 3 mg/kg in 3 week intervals. Tumor assessments were conducted at baseline, weeks 12, 24, 36 and 48 according to RECIST 1.1 criteria. Adverse events (AEs), including immune-related AEs were graded according to National Cancer Institute Common Toxicity Criteria (CTC) v.4.0. Primary endpoint was the OS rate at 12 months. Results: Forty five pretreated (85%) and eight treatment-naïve (15%) patients received at least one dose of ipilimumab. 1-year and 2-year OS rates were 22% and 7%, respectively. Median OS was 6.8 months (95% CI 3.7-8.1), median progression-free survival 2.8 months (95% CI 2.5-2.9). The disease control rate at weeks 12 and 24 was 47% and 21%, respectively. Sixteen patients had stable disease (47%), none experienced partial or complete response. Treatment-related AEs were observed in 35 patients (66%), including 19 grade 3-4 events (36%). One drug-related death due to pancytopenia was observed. Conclusions: Ipilimumab has very limited clinical activity in patients with metastatic UM. Toxicity was manageable when treated as per protocol-specific guidelines. Trial Registration: ClinicalTrials.gov NCT01355120 | ||
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 700 | 1 | |a Enk, Alexander |d 1963- |e VerfasserIn |0 (DE-588)1032757140 |0 (DE-627)739272535 |0 (DE-576)166173517 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PLOS ONE |d San Francisco, California, US : PLOS, 2006 |g 10(2015,3) Artikel-Nummer e0118564, 13 Seiten |h Online-Ressource |w (DE-627)523574592 |w (DE-600)2267670-3 |w (DE-576)281331979 |x 1932-6203 |7 nnas |a Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma |
| 773 | 1 | 8 | |g volume:10 |g year:2015 |g number:3 |g extent:13 |a Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pone.0118564 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356548/ |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170830 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 1032757140 |a Enk, Alexander |m 1032757140:Enk, Alexander |d 910000 |d 911300 |e 910000PE1032757140 |e 911300PE1032757140 |k 0/910000/ |k 1/910000/911300/ |p 9 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 5 | ||
| 999 | |a KXP-PPN1562886649 |e 2978863226 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"March 11, 2015","dateIssuedKey":"2015"}],"language":["eng"],"id":{"eki":["1562886649"],"doi":["10.1371/journal.pone.0118564"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"13 S."}],"person":[{"given":"Lisa","display":"Zimmer, Lisa","family":"Zimmer","role":"aut"},{"given":"Jochen","family":"Utikal","display":"Utikal, Jochen","role":"aut"},{"display":"Enk, Alexander","family":"Enk","given":"Alexander","role":"aut"}],"title":[{"title":"Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma","title_sort":"Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma"}],"relHost":[{"disp":"Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaPLOS ONE","name":{"displayForm":["Public Library of Science"]},"pubHistory":["1.2006 -"],"recId":"523574592","note":["Schreibweise des Titels bis 2012: PLoS ONE","Gesehen am 20.03.19"],"origin":[{"dateIssuedKey":"2006","publisher":"PLOS ; PLoS","publisherPlace":"San Francisco, California, US ; Lawrence, Kan.","dateIssuedDisp":"2006-"}],"title":[{"title":"PLOS ONE","title_sort":"PLOS ONE"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"10(2015,3) Artikel-Nummer e0118564, 13 Seiten","issue":"3","year":"2015","extent":"13","volume":"10"},"language":["eng"],"id":{"eki":["523574592"],"zdb":["2267670-3"],"issn":["1932-6203"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"Public Library of Science","role":"isb"}]}],"name":{"displayForm":["Lisa Zimmer, Julia Vaubel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus G. Griewank, Michael Fluck, Bastian Schilling, Dirk Schadendorf"]},"note":["Gesehen am 30.08.2017"],"recId":"1562886649"} | ||
| SRT | |a ZIMMERLISAPHASEIIDEC1120 | ||